Key Takeaways:
- The Trump administration has unveiled new actions aimed at eliminating transition-related medical care for minors across the US.
- The Centers for Medicare and Medicaid Services will initiate a rule-making process to prevent hospitals from offering puberty blockers, hormone treatments, or surgical procedures to minors.
- The proposal would also prohibit Medicaid funds from being used to cover this type of care.
- The Food and Drug Administration (FDA) will send warnings to 12 companies that manufacture or sell breast binders intended for minors to treat gender dysphoria.
- The administration is taking steps to reverse a policy established during the Biden administration that classified gender dysphoria as a disability under federal law.
Introduction to the Trump Administration’s New Actions
The Trump administration has announced new actions aimed at eliminating transition-related medical care for minors across the US. The administration refers to such treatments as "sex-rejecting procedures", a term used by the Department of Health and Human Services (HHS). As part of the effort, the Centers for Medicare and Medicaid Services will initiate a rule-making process that would prevent hospitals from offering puberty blockers, hormone treatments, or surgical procedures to minors if they wish to participate in Medicare or Medicaid. This move has been met with heavy criticism from health experts, lawmakers, and LGBTQ+ rights organizations.
The Proposal and Its Implications
The proposal would also prohibit Medicaid funds from being used to cover this type of care. Medicaid and the Children’s Health Insurance Program (Chip) together cover nearly half of all American children. The administration claims that these procedures are "unsafe" and "irreversible", and that they put children at risk. However, most major US medical organizations support access to such care and have criticized efforts to restrict it. The American Medical Association and the American Academy of Pediatrics have both spoken out against the administration’s actions, stating that gender-affirming care is a vital and necessary treatment for many young people.
The FDA’s Role in the Proposal
The Food and Drug Administration (FDA) will also play a role in the proposal, sending warnings to 12 companies that manufacture or sell breast binders intended for minors to treat gender dysphoria. The department alleges that these companies are engaging in illegal marketing practices. The FDA’s actions are seen as a further attempt to restrict access to transition-related medical care for minors. The use of breast binders is a common practice among young people who are transitioning, and the FDA’s actions may make it more difficult for them to access these products.
Reversing the Biden Administration’s Policy
The administration is also taking steps to reverse a policy established during the Biden administration that classified gender dysphoria as a disability under federal law. A newly proposed update to Section 504 of the Rehabilitation Act of 1973 would specify that "disability" and "individual with a disability" do not include gender dysphoria unless it stems from a physical impairment. This move is seen as a further attempt to restrict the rights of transgender individuals and limit their access to necessary medical care.
Criticism and Opposition
The administration’s actions have been met with widespread criticism and opposition. Health experts, lawmakers, and LGBTQ+ rights organizations have all spoken out against the proposal, stating that it is a "deliberate and targeted attack" on transgender youth and their families. Dr. Jamila Perritt, an OB/GYN and the CEO of Physicians for Reproductive Health, stated that "gender-affirming care is lifesaving care" and that the proposal is a "lose-lose situation where lives are inevitably on the line". Rodrigo Heng-Lehtinen, the senior vice-president of public engagement campaigns at the Trevor Project, stated that "everyone in this country should have access to the care they need to stay healthy, including transgender and nonbinary young people".
The Broader Context
The administration’s actions are part of a larger effort to limit access to transition-related medical care for both children and adults. During the opening weeks of his second term, Donald Trump signed several executive orders focused on transgender issues, including one asserting that only two sexes exist and another that barred federal funds from going to hospitals that provide transition-related care to minors. The House has also passed legislation that prohibits people under the age of 18 from receiving gender-affirming care and prohibits Medicaid from funding gender-affirming care for minors. However, neither bill is expected to receive enough Democratic support to advance through the Senate.
Conclusion
In conclusion, the Trump administration’s new actions aimed at eliminating transition-related medical care for minors are a significant and concerning development. The proposal and the FDA’s actions are seen as a further attempt to restrict access to necessary medical care for young people who are transitioning. The administration’s actions have been met with widespread criticism and opposition, and it remains to be seen how these actions will ultimately play out. However, one thing is clear: the administration’s actions will have a significant impact on the lives of transgender young people and their families, and it is essential that we continue to speak out against these attacks and advocate for the rights and dignity of all individuals, regardless of their gender identity.